Table 1.
Baseline demographic, clinical characteristics and laboratory parameters of study groups.
| Variables | Low thrombus burden (n = 120) | High thrombus burden (n = 96) | P |
|---|---|---|---|
| Age (yr) | 57 ± 9.3 | 63.8 ± 9 | <.001 |
| Male, n (%) | 74 (61.7%) | 58 (60.4%) | .851 |
| Diabetes mellitus, n (%) | 42 (35%) | 38 (39.6%) | .488 |
| Hypertension, n (%) | 41 (34.2%) | 45 (46.9%) | .058 |
| Smokers, n (%) | 37 (30.8%) | 23 (24%) | .262 |
| Hyperlipidemia, n (%) | 46 (38.3%) | 39 (40.6%) | .241 |
| Family history of CAD, n (%) | 35 (29.2%) | 33 (34.4%) | .413 |
| Medical history, n (%) | |||
| Acetylsalic acid | 35 (29.2%) | 25 (26%) | .610 |
| Statin | 32 (26.7%) | 20 (20.8%) | .319 |
| Beta-blocker | 37 (30.8%) | 29 (30.2%) | .921 |
| ACEI/ARB | 32 (26.7%) | 34 (35.4%) | .165 |
| CCB | 19 (15.8%) | 15 (15.6%) | .902 |
| İRA, n (%) | |||
| LAD | 45 (37.5%) | 43 (44.8%) | .524 |
| LCX | 32 (26.7%) | 21 (21.9%) | |
| RCA | 43 (35.8%) | 32 (33.3%) | |
| SYNTAX score | 15.1 (10.3–18) | 20.3 (15.6–25) | <.001 |
| BMI (kg/m2) | 27.7 (25–30.3) | 26.9 (24.2–29.2) | .118 |
| Stent diameter (mm) | 3.09 ± 0.33 | 2.98 ± 0.27 | .210 |
| Stent length (mm) | 22.8 ± 7.02 | 23.1 ± 6.71 | .546 |
| Pain to ballon time (min) | 55.2 (45–60) | 59.1 (40–78.8) | .564 |
| LVEF (%) | 44.9 (40–48) | 41.3 (35.8–45) | <.001 |
| Baseline cTnT (ng/mL) | 285 (100–325) | 596 (203–733) | <.001 |
| Peak cTn T (ng/mL) | 3225 (1890–4801) | 5911 (4031–8412) | <.001 |
| CRP (mg/dL) | 3.8 (2.2–5.1) | 4.5 (2.3–6) | .016 |
| Albumin (d/L) | 3.9 (3.8–4.2) | 3.8 (3.5–4.1) | .001 |
| CAR | 0.93 (0.62–1.23) | 1.33 (1.03–1.61) | <.001 |
| Glucose (mg/dL) | 137.5 ± 50.5 | 148.3 ± 54.1 | .023 |
| Creatinine (mg/dL) | 0,91 ± 0.26 | 0.97 ± 0.25 | .093 |
| Hemoglobin (g/dL) | 13.3 ± 1.41 | 12.8 ± 1.51 | .101 |
| WBC (×103 µL) | 11.2 ± 1.7 | 12.6 ± 2.1 | <.001 |
| NLR | 1.76 (1.1–2.1) | 2.85 (2.07–3.76) | <.001 |
| Platelet (×103 µL) | 218 ± 65 | 212 ± 71 | .233 |
| Total cholesterol (mg/dL) | 194.8 ± 32.3 | 198.1 ± 28.3 | .445 |
| Triglyceride (mg/dL) | 183.4 ± 40 | 187.1 ± 45 | .102 |
| LDL-C (mg/dL) | 142.5 ± 24.1 | 145 ± 21.8 | .441 |
| HDL-C (mg/dL) | 35.6 ± 5.8 | 36.1 ± 6.4 | .556 |
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, BMI = body mass index, CAD = coronary artery disease, CAR = C-reactive protein to albumin ratio, CCB = calcium channel blockers, CK-MB = creatine kinase muscle brain, CRP = C-reactive protein, CTFC = correct thrombolysis in myocardial infarction frame count, CX = left circumflex artery, HDL-C = high-density lipoprotein cholesterol, IRA = İnfarct-related artery, LAD = Left anterior descending artery, LDL-C = low-density lipoprotein cholesterol, LVEF = left ventricular ejection fraction, MBG = angiographically myocardial blush grade, NLR = Neutrophil–lymphocyte ratio, RCA = right coronary artery, SYNTAX = SYNergy between percutaneous coronary interventin with TAXus, WBC = white blood cell.
P values in bold indicate clinical significance.